Equities Analysts Issue Forecasts for NBIX Q4 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $1.06 for the quarter, down from their previous estimate of $1.20. HC Wainwright currently has a “Buy” rating and a $185.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ FY2026 earnings at $4.43 EPS, FY2027 earnings at $7.33 EPS and FY2029 earnings at $14.69 EPS.

Several other research firms have also recently weighed in on NBIX. Barclays raised their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. UBS Group raised their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Bank of America decreased their price objective on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada dropped their price objective on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a report on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX opened at $119.11 on Monday. The business has a fifty day moving average of $136.35 and a 200-day moving average of $129.11. The firm has a market cap of $11.88 billion, a PE ratio of 36.20, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%.

Neurocrine Biosciences declared that its Board of Directors has initiated a share buyback program on Friday, February 21st that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to buy up to 4.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Insider Activity at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 2,707 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the sale, the director now owns 517,030 shares in the company, valued at approximately $79,064,227.60. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Ingrid Delaet sold 272 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now directly owns 2,507 shares in the company, valued at approximately $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 236,600 shares of company stock valued at $34,348,261. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

Several hedge funds have recently added to or reduced their stakes in NBIX. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock worth $1,381,331,000 after buying an additional 122,681 shares during the period. State Street Corp grew its stake in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after acquiring an additional 539,936 shares in the last quarter. Dodge & Cox increased its position in Neurocrine Biosciences by 134.2% during the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after acquiring an additional 1,728,605 shares during the period. AQR Capital Management LLC raised its stake in Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company’s stock worth $258,926,000 after purchasing an additional 53,610 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Neurocrine Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock worth $255,523,000 after purchasing an additional 15,830 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.